Join to view full profile
650 W 168th StBb-1427 Dept Pathology Columbia UniversityNew York, NY 10032
Phone+1 212-305-0395
Fax+1 212-305-5498
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Brett Lauring, MD is a board certified pathologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1996 - 2001
New York University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2021
American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 42 citationsSafety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang
Diabetes, Obesity & Metabolism. 2019-06-01 - 55 citationsLong-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck
Diabetes, Obesity & Metabolism. 2019-04-01 - 30 citationsResults of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus i...Priscilla Hollander, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory T. Golm
Current Medical Research and Opinion. 2019-03-25
Press Mentions
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of MigraineDecember 8th, 2025
Kallyope Inc. Appoints Brett Lauring as Chief Medical OfficerFebruary 5th, 2019- Kallyope Enters Phase 2 with First-in-Class Oral Approach for the Treatment of Both Obesity and Type 2 DiabetesSeptember 28th, 2023
